Novabridge Presents Positive Givastomig Dose Expansion Data From the Phase 1B Combination Study in Patients With 1L Metastatic Gastric Cancer
Novabridge Presents Positive Givastomig Dose Expansion Data From the Phase 1B Combination Study in Patients With 1L Metastatic Gastric Cancer
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.